近年来转移性结直肠癌靶向治疗研究进展  

Recent Research Progress in Targeted Ther-apy of Metastatic Colorectal Cancer

作　　者：张婷婷 郭建强[1] 

机构地区：[1]山东大学第二医院消化内科,山东 济南

出　　处：《临床医学进展》2023年第6期10321-10328,共8页Advances in Clinical Medicine

摘　　要：结直肠癌(colorectal cancer, CRC)是常见消化系统肿瘤,发病具有隐匿性,转移是导致结直肠癌患者死亡的一个主要原因,在整个疾病进程中几乎一半的患者会发生转移,约25%患者确诊时已处于晚期阶段,出现病灶转移。转移性结直肠癌(mCRC)通常无手术机会且传统化疗效果欠佳,病死率高。目前临床治疗mCRC主要依靠放疗、化疗及分子靶向治疗综合治疗,近年来分子靶向治疗成为mCRC治疗新方向,尤其是近年来分子靶向药物贝伐珠单抗及西妥昔单抗问世并广泛应用于临床,mCRC预后显著改善。本文就目前mCRC靶向治疗的研究进展进行综述,以期为临床诊疗提供依据。Colorectal cancer (CRC) is a common digestive system tumor with occult onset, and metastasis is a major cause of death in colorectal cancer patients. In the entire course of the disease, almost half of patients have metastases, and about 25% of patients are diagnosed with colorectal cancer in the advanced stage, focus metastasis. Metastatic colorectal cancer (mCRC) usually has no surgical op-portunity and is less effective with conventional chemotherapy, with high mortality. Currently, the clinical treatment of mCRC mainly relies on the combination of radiotherapy, chemotherapy and molecular targeted therapy. In recent years, molecular targeted therapy has become a new direc-tion of mCRC treatment, especially in recent years, molecular targeted drugs bevacizumab and ce-tuximab have been developed and widely used in clinic, and the prognosis of mCRC has been signif-icantly improved. This article reviews the current research progress of mCRC targeted therapy, in order to provide evidence for clinical diagnosis and treatment.

关 键 词：转移性结直肠癌 靶向治疗 免疫检查点抑制 

分 类 号：R73[医药卫生—肿瘤]